Generic-drug maker Akorn is among a few stocks in the Spotlight screen that is working on a base. Even better, the pattern is second stage, which has a better chance of success than a base that forms later in a stock’s advance. The potential buy point is at 45.35. Akorn (AKRX) stock boasts strong fundamentals.